In response to: Multiple assays in a real-time RT-PCR severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) panel can mitigate the risk of loss of sensitivity by new genomic variants during the COVID-19 outbreak

• Luis Peñarrubia,
• Maria Ruiz,
• Roberto Porco,
• Sonia N. Rao,
• Stephen A. Vella,
• Martí Juanola-Falgarona,
• Davide Manissero,
• Marta López-Fontanals,
• Josep Pareja

Affiliations

Luis Peñarrubia

STAT-Dx Life, S.L. (a QIAGEN Company), Barcelona, Spain

Maria Ruiz

STAT-Dx Life, S.L. (a QIAGEN Company), Barcelona, Spain

Roberto Porco

STAT-Dx Life, S.L. (a QIAGEN Company), Barcelona, Spain

Sonia N. Rao

QIAGEN, Inc., Germantown, MD, USA

Stephen A. Vella

QIAGEN, Inc., Germantown, MD, USA

Martí Juanola-Falgarona

STAT-Dx Life, S.L. (a QIAGEN Company), Barcelona, Spain

Davide Manissero

QIAGEN Manchester Ltd, Manchester, UK

Marta López-Fontanals

STAT-Dx Life, S.L. (a QIAGEN Company), Barcelona, Spain

Josep Pareja

Corresponding author.; STAT-Dx Life, S.L. (a QIAGEN Company), Barcelona, Spain